



## Elevate Your Vaccine Research With Elligo

### Patient Access. Elite Sites. Expert Support.

Elligo Health Research® enhances vaccine trials through healthcare with diverse patient identification, enrollment, and retention, and the seamless delivery of high-quality data from our expansive network.

#### 20 Elite Healthcare-First Vaccine Sites Across 11 States

- Several with local peripheral blood mononuclear cell (PBMC) capabilities
- Provides research as care to millions of untapped, underrepresented patients
- Healthcare-first sites span North America, offering geographic, socioeconomic, and racial/ethnic diversity

***30%+ minority representation through nontraditional patient access.***

#### Expedited, Seamless Site Selection and Rapid Study Startup

- **One contract and budget across all sites**
- Centralized Elligo site outreach, feasibility, and interest assessments
- Streamlined PI engagement at the point of identification

#### Improved Patient Access and Retention

- HIPAA-compliant EHR data verifies patients upfront
- Outreach, screening, and engagement support as needed
- Focus on “known” patients whose treating physician also serves as the PI – preserves the valuable physician and patient relationship to ensure long-term protocol adherence and retention

***87% average retention rate across all studies, including long-term outcomes trials.***

#### End-to-End Excellence

- Elligo team members are integrated with the PI and local team in support of quality clinical delivery
- Central patient engagement teams support recruitment
- Elligo study navigators provide oversight throughout the trial

***99% first regulatory submission success rate and record of 0 critical findings or 483s from FDA Inspections and Sponsor Audits.***



## Proprietary Technology

### IntElligo® eSource Data Collection

- Deployed across sites
- eSource data collection capability with embedded flexibility to facilitate site workflow
- Supports trial management
- Enables the efficient flow of information, workflow, and logistics
- Option for remote monitoring via a single platform

### Root Health Direct-to-Patient Communication

- Early patient engagement and connectivity through the duration of the trial

## Your Trial Is in Good Hands

Elligo has performed over 105 vaccine trials with more than 125 PIs involved and 10,419 patients enrolled – and counting.

Our vaccine experience includes:

- COVID-19
- Meningitis
- Human papillomavirus (HPV)
- RSV
- Influenza
- Pneumococcal

## Elligo's Largest Enrolling Vaccine Trial to Date

Influenza research with:

- 840 consented with 809 active
- 2% screen fail rate
- 3,327 visits to date with 97% in-window

## Elligo's Diverse & Highly Qualified COVID-19 Vaccine Trial Enrollment

- Elligo's enrollment was extended while other sites were ramped down
- Over 600 participants were screened across two sites over 10 weeks
- Approximately 583 participants enrolled
- **Screen fail rate of ~3%**
- One site enrolled ~90% Hispanic/Latino participants

**When you need direct access to known patients, elite sites, and the best support for your vaccine trial, there's Only Elligo.**

**ELEVATE YOUR VACCINE RESEARCH**

### About Elligo Health Research®

Elligo Health Research accelerates clinical trials through EHR data, our proprietary IntElligo® technology, and direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. Our Patient*Select*® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Our Site*Select* model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.